カテゴリ： GlobalData, アメリカ, 企業調査

AveXis Inc (AVXS)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：AveXis Inc (AVXS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9996
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：78
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
AveXis Inc (AveXis), formerly BioLife Cell Bank Inc, is a biotechnology company that develops innovative treatments for rare and potentially fatal neurological genetic diseases. The company offers AVXS-101, a proprietary gene therapy candidate in phase 1 targeted at the treatment of spinal muscular atrophy. Its AVXS-101 received orphan drug designation for the treatment of all types of SMA from the US FDA; fast track designation for the treatment of SMA Type 1; and breakthrough therapy designation for the treatment of SMA Type 1 in pediatric patients. It works in collaboration with various academic institutes and research centers to advance its investigational product candidates. AveXis is headquartered in Bannockburn, Illinois, the US.

AveXis Inc (AVXS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AveXis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AveXis Inc, Medical Devices Deals, 2012 to YTD 2018 10
AveXis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
AveXis Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
AveXis Raises USD65 Million in Venture Financing 13
AveXis Raises USD10 Million in Series C Financing Round 15
Partnerships 16
AveXis Enters into Licensing Agreement with Genethon and Centre National de la Recherche Scientifique 16
Licensing Agreements 17
AveXis Enters into Licensing Agreement with Regenxbio 17
AveXis Enters into Licensing Agreement with Nationwide Children’s Hospital for Development of Rett syndrome 19
AveXis Enters into Licensing Agreement with Nationwide Children’s Hospital for Development of Amyotrophic Lateral Sclerosis 20
Asklepios BioPharma Enters into Licensing Agreement with AveXis 21
AveXis Amends Licensing Agreement With ReGenX Biosciences 22
AveXis Amends Licensing Agreement with Nationwide Children’s Hospital 23
Equity Offering 24
AveXis Raises USD460 Million in Public Offering of Shares 24
AveXis Raises USD287.8 Million in Public Offering of Shares 26
AveXis Raises USD146.6 Million in Public Offering of Shares 28
AveXis Completes Underwriter’s Exercise of Over-Allotment Option of IPO 30
AveXis Raises USD2 Million in Private Placement of Shares and Warrants 31
Debt Offering 32
AveXis Raises USD0.5 Million in Private Placement of 8% Notes 32
Acquisition 33
Novartis Acquires AveXis for USD8.7 Billion 33
AveXis Inc – Key Competitors 35
AveXis Inc – Key Employees 36
AveXis Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Financial Announcements 38
May 03, 2018: AveXis Reports First Quarter 2018 Financial and Operating Results 38
Feb 27, 2018: AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results 40
Nov 09, 2017: AveXis Reports Third Quarter 2017 Financial and Operating Results 42
Aug 10, 2017: AveXis Reports Second Quarter 2017 Financial and Operating Results 44
May 11, 2017: AveXis Reports First Quarter 2017 Financial and Operating Results 46
Corporate Communications 48
Feb 15, 2017: AveXis Appoints Rick Modi as Senior Vice President and Chief Business Officer 48
Product Approvals 49
Mar 27, 2018: AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1 49
Jan 04, 2018: AveXis Announces Alignment with FDA on Next Steps Toward a BLA Submission for AVXS-101 in SMA Type 1 50
Jun 14, 2017: AveXis Announces Alignment with FDA on GMP Commercial Manufacturing Process for AVXS-101 51
Jan 31, 2017: AveXis Gene Therapy AVXS-101 Granted Access into EMA PRIME Program for Spinal Muscular Atrophy Type 1 53
Clinical Trials 54
May 08, 2018: AveXis Issues Community Statement on the SPR1NT Trial 54
Apr 25, 2018: AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3 55
Apr 24, 2018: AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology 57
Apr 19, 2018: AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology 59
Jan 30, 2018: AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients 60
Jan 16, 2018: AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy 61
Dec 13, 2017: AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101 62
Nov 01, 2017: AveXis Announces New England Journal of Medicine Publication of Phase 1 Data of AVXS-101 Gene Replacement Therapy in Spinal Muscular Atrophy Type 1 64
Oct 03, 2017: AveXis to Report Top-line Data from the Phase 1 Clinical Trial of AVXS-101 in SMA Type 1 at the International Annual Congress of the World Muscle Society 66
Sep 29, 2017: AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial Process 67
Apr 25, 2017: AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology 69
Apr 18, 2017: AveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual Meeting of the American Academy of Neurology 71
Mar 16, 2017: AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results 72
Mar 09, 2017: AveXis to Report Topline Phase 1 Trial Results in SMA Type 1 75
Mar 02, 2017: AveXis to Present Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at AAN Annual Meeting 76
Feb 06, 2017: AveXis Announces Single-Arm Design for European Pivotal Study of AVXS-101 in SMA Type 1 Patients 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78

List of Tables
AveXis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AveXis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AveXis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
AveXis Inc, Medical Devices Deals, 2012 to YTD 2018 10
AveXis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
AveXis Raises USD65 Million in Venture Financing 13
AveXis Raises USD10 Million in Series C Financing Round 15
AveXis Enters into Licensing Agreement with Genethon and Centre National de la Recherche Scientifique 16
AveXis Enters into Licensing Agreement with Regenxbio 17
AveXis Enters into Licensing Agreement with Nationwide Children’s Hospital for Development of Rett syndrome 19
AveXis Enters into Licensing Agreement with Nationwide Children’s Hospital for Development of Amyotrophic Lateral Sclerosis 20
Asklepios BioPharma Enters into Licensing Agreement with AveXis 21
AveXis Amends Licensing Agreement With ReGenX Biosciences 22
AveXis Amends Licensing Agreement with Nationwide Children's Hospital 23
AveXis Raises USD460 Million in Public Offering of Shares 24
AveXis Raises USD287.8 Million in Public Offering of Shares 26
AveXis Raises USD146.6 Million in Public Offering of Shares 28
AveXis Completes Underwriter’s Exercise of Over-Allotment Option of IPO 30
AveXis Raises USD2 Million in Private Placement of Shares and Warrants 31
AveXis Raises USD0.5 Million in Private Placement of 8% Notes 32
Novartis Acquires AveXis for USD8.7 Billion 33
AveXis Inc, Key Competitors 35
AveXis Inc, Key Employees 36
AveXis Inc, Subsidiaries 37

List of Figures
AveXis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AveXis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AveXis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AveXis Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[AveXis Inc (AVXS)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Origin Enterprises PLC：企業のM&A・事業提携・投資動向
    Origin Enterprises PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Origin Enterprises PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Autoridad del Canal de Panama：企業の戦略的SWOT分析
    Autoridad del Canal de Panama - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Regal Hotels International Holdings Ltd：企業の戦略・SWOT・財務情報
    Regal Hotels International Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Regal Hotels International Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Topdanmark AS (TOP)：企業の財務・戦略的SWOT分析
    Topdanmark AS (TOP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Symetra Life Insurance Company：企業の戦略・SWOT・財務情報
    Symetra Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Symetra Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Broadridge Financial Solutions, Inc.：企業のM&A・事業提携・投資動向
    Broadridge Financial Solutions, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Broadridge Financial Solutions, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • Ampio Pharmaceuticals Inc (AMPE)：企業の財務・戦略的SWOT分析
    Summary Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by …
  • ARRIS International PLC：企業の戦略的SWOT分析
    ARRIS International PLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Veloxis Pharmaceuticals AS (VELO)：製薬・医療：M&Aディール及び事業提携情報
    Summary Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company that identifies, develops and commercializes pharmaceutical drugs in transplantation and adjacent therapies. The company developed ENVARSUS XR (tacrolimus extended-release tablets) for the prophylaxis of organ reject …
  • Nipro Corp (8086)：製薬・医療：M&Aディール及び事業提携情報
    Summary Nipro Corp (Nipro) manufactures, develops and markets pharmaceuticals, medical equipment and functional materials (including glass, rubber and plastic). The company’s products include renal products, interventional and anesthesiology products, injection and infusion products, cardiopulmonary …
  • Royal DSM NV (DSM)：医療機器：M&Aディール及び事業提携情報
    Summary Royal DSM NV (DSM) is a science-based company with focus on materials, health and nutrition. It produces vitamins, carotenoids, nutritional lipids and other ingredients; specialty plastics; and fiber and resins solutions. DSM develops materials for medical devices and clean energy from crop …
  • MAN Energy Solutions SE：企業の戦略的SWOT分析
    MAN Energy Solutions SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • iNova Pharmaceuticals (Australia) Pty Ltd：企業の戦略的SWOT分析
    iNova Pharmaceuticals (Australia) Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Adimmune Corp (4142)：製薬・医療：M&Aディール及び事業提携情報
    Summary Adimmune Corp (Adimmune) is a biopharmaceutical company that manufactures diagnostics, vaccines, and biological products for various diseases. The corporation’s products include tetanus toxoid adsorbed vaccine, influenza vaccine, Japan encephalitis vaccine, and ah1n1 vaccine. It also provide …
  • Norgine B.V.：企業のM&A・事業提携・投資動向
    Norgine B.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Norgine B.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Nanophase Technologies Corp (NANX)：企業の財務・戦略的SWOT分析
    Nanophase Technologies Corp (NANX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Misen Energy AB (MISE)：企業の財務・戦略的SWOT分析
    Summary Misen Energy AB (Misen) is an oil and gas company that provides pipeline services. The company offers production of gas and oil fields by implementation of large-scale investment programs and introduction of modern western knowhow and technology. It provides development of new and redevelopm …
  • PowerVision Inc：医療機器：M&Aディール及び事業提携情報
    Summary PowerVision Inc (PowerVision) is a medical device company which focused on developing fluid-based accommodating intraocular lenses (AIOL) for presbyopia and cataracts patients. The company offers FluidVision accommodating intraocular lens technology which provides true accommodation by imita …
  • Fabric Development Inc：企業の戦略的SWOT分析
    Fabric Development Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Bayer AG (BAYN)-医療機器分野：企業M&A・提携分析
    Summary Bayer AG (Bayer) carries out the research, development, production and commercialization of products in the areas of human and animal health care, and agriculture. It provides pharmaceuticals for cardiology, women’s healthcare, oncology, hematology, ophthalmology, infection and other indicat …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆